KaloBios distancing itself from Martin Shkreli with new drug pricing model
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
Monoclonal antibody player KaloBios shutting down
The long-beleaguered monoclonal antibody developer KaloBios is finally winding down operations - after a constant stream of setbacks since its February 2013 IPO.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.